Wynn Capital LLC Purchases New Position in Pfizer Inc. (NYSE:PFE)

Wynn Capital LLC acquired a new stake in Pfizer Inc. (NYSE:PFE) in the fourth quarter, Holdings Channel reports. The fund acquired 21,423 shares of the biopharmaceutical company’s stock, valued at approximately $617,000.

A number of other institutional investors have also recently bought and sold shares of the business. Mizuho Securities Co. Ltd. boosted its holdings in Pfizer by 261.7% in the 4th quarter. Mizuho Securities Co. Ltd. now owns 3,700 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 2,677 shares during the period. Fountainhead AM LLC bought a new stake in Pfizer in the 4th quarter valued at about $551,000. Private Management Group Inc. boosted its holdings in Pfizer by 5.9% in the 4th quarter. Private Management Group Inc. now owns 7,170 shares of the biopharmaceutical company’s stock valued at $206,000 after purchasing an additional 399 shares during the period. South Dakota Investment Council boosted its position in shares of Pfizer by 33.4% during the 4th quarter. South Dakota Investment Council now owns 1,246,648 shares of the biopharmaceutical company’s stock worth $35,891,000 after acquiring an additional 312,410 shares in the last quarter. Finally, NewSquare Capital LLC boosted its position in shares of Pfizer by 3.0% during the 4th quarter. NewSquare Capital LLC now owns 147,446 shares of the biopharmaceutical company’s stock worth $4,190,000 after acquiring an additional 4,354 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on PFE shares. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Guggenheim began coverage on shares of Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Monday, April 15th. Finally, TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research report on Thursday, January 4th. Eleven analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, Pfizer presently has an average rating of “Hold” and an average target price of $36.33.

Pfizer Trading Down 0.2 %

Shares of PFE stock traded down $0.06 during trading hours on Wednesday, hitting $26.26. 24,501,011 shares of the company’s stock traded hands, compared to its average volume of 41,887,898. Pfizer Inc. has a 12 month low of $25.23 and a 12 month high of $40.37. The stock’s 50 day simple moving average is $27.07 and its 200 day simple moving average is $28.52. The stock has a market cap of $148.70 billion, a PE ratio of 72.97, a price-to-earnings-growth ratio of 1.18 and a beta of 0.61. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. During the same quarter last year, the firm earned $1.14 earnings per share. Pfizer’s quarterly revenue was down 41.3% on a year-over-year basis. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be paid a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 6.40%. Pfizer’s dividend payout ratio is presently 466.67%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.